Table 1.
Characteristics at initiation and at viral suppression among 4129 patients initiating ART at the Themba Lethu Clinic in Johannesburg, South Africa
| Characteristics | Total | Males | Females | |
|---|---|---|---|---|
| Characteristics at ART initiation | ||||
| Total | 4129 | 1478 (35.8%) | 2651 (64.2%) | |
| Black race, n (%) | 3939 (95.4%) | 1401 (94.8%) | 2538 (95.7%) | |
| Employed, n (%) | 1783 (43.2%) | 730 (49.4%) | 1053 (39.7%) | |
| Hb | <10 g/dl, n (%) | 983 (23.8%) | 245 (17.0%) | 738 (28.7%) |
| ≥10 g/dl, n (%) | 3030 (73.4%) | 1196 (83.0%) | 1834 (71.3%) | |
| CD4 | <50 cells/ml, n (%) | 1490 (36.1%) | 630 (42.6%) | 860 (32.4%) |
| 50–199 cells/ml, n (%) | 2337 (56.6%) | 758 (51.3%) | 1579 (59.6%) | |
| ≥200 cells/ml, n (%) | 302 (7.3%) | 90 (6.1%) | 212 (8.0%) | |
| BMI | <18.5 kg/m2, n (%) | 654 (18.9%) | 307 (24.6%) | 347 (15.7%) |
| ≥18.5 kg/m2, n (%) | 2807 (81.1%) | 941 (75.4%) | 1866 (84.3%) | |
| Age | 18–35 years | 278 (6.7%) | 138 (9.3%) | 140 (5.3%) |
| 36–55 years | 2845 (68.9%) | 1109 (75.0%) | 1736 (65.4%) | |
| >55 years | 1006 (24.4%) | 231 (15.6%) | 775 (29.2%) | |
| WHO | Stage I/II, n (%) | 2173 (52.6%) | 702 (47.5%) | 1471 (55.5%) |
| Stage III/IV, n (%) | 1956 (47.4%) | 776 (52.5%) | 1180 (44.5%) | |
| Regimen | EFV-3TC-d4T, n (%) | 3681 (89.2%) | 1368 (92.2%) | 2318 (87.4%) |
| EFV-3TC-AZT, n (%) | 340 (8.2%) | 72 (4.9%) | 268 (10.1%) | |
| NVP-3TC-d4T, n (%) | 98 (2.4%) | 42 (2.8%) | 56 (2.1%) | |
| NVP-3TC-AZT, n (%) | 10 (0.2%) | 1 (0.1%) | 9 (0.3%) | |
| Age (years), median (IQR) | 39 (34–46) | 41.1 (36.8–47.0) | 39.0 (34.2–45.0) | |
| Hb g/dl, median (IQR) | 11.6 (10.1–13) | 12.4 (10.7–14.0) | 11.2 (9.8–12.6) | |
| CD4 count, median (IQR) | 80 (29–146) | 69 (21–136) | 87 (35–152) | |
| BMI kg/m2, median (IQR) | 21.5 (19.1–24.5) | 20.3 (18.5–22.6) | 22.4 (19.6–25.5) | |
| Characteristics at six months post-ART initiation | ||||
| Hb | <10 g/dl, n (%) | 615 (15.1%) | 129 (8.9%) | 486 (18.6%) |
| ≥10 g/dl, n (%) | 3446 (84.9%) | 1325 (91.1%) | 2121 (81.4%) | |
| CD4 | <50 cells/ ml, n (%) | 130 (3.2%) | 79 (5.4%) | 51 (2.0%) |
| 50–199 cells/ ml, n (%) | 1888 (45.7%) | 756 (51.2%) | 1132 (42.7%) | |
| ≥200 cells/ml, n (%) | 2111 (51.1%) | 643 (43.5%) | 1468 (55.4%) | |
| BMI | <18.5 kg/m2, n (%) | 654 (18.9%) | 307 (24.6%) | 347 (15.7%) |
| ≥18.5 kg/m2, n (%) | 2807 (81.1%) | 941 (75.4%) | 1886 (84.3%) | |
| Hb g/dl, median (IQR) | 12.1 (10.3–14) | 12.6 (10.7–14.3) | 11.9 (10.2–13.8) | |
| CD4 count, median (IQR) | 202 (133–286) | 181 (113–262) | 216 (146–298) | |
| BMI kg/m2, median (IQR) | 23.7 (21.1–27) | 22.1 (20.3–24.7) | 24.8 (21.9–28.3) | |
ART, antiretroviral therapy; Hb, haemoglobin; BMI, body mass index; EFV, efavirenz; 3TC, lamivudine; d4T, stavudine; AZT, zidovudine; NVP, nevirapine; IQR, inter-quartile range.